Invitae Corporation (NVTAQ) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, Invitae Corporation (NVTAQ) es una empresa del sector Healthcare valorada en 0. Calificado con 41/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 18 mar 2026Invitae Corporation (NVTAQ) Resumen de Asistencia Médica y Tuberías
Invitae Corporation provides genetic testing services across various clinical areas, including hereditary cancer and rare diseases, serving patients, healthcare providers, and biopharma companies. Currently undergoing Chapter 11 reorganization, the company faces significant financial challenges within the competitive medical diagnostics market.
Tesis de Inversión
Invitae Corporation's Chapter 11 filing introduces significant uncertainty regarding its future. Key value drivers include its comprehensive genetic testing services and partnerships within the healthcare ecosystem. Growth catalysts involve potential restructuring efficiencies and strategic realignment. However, the company faces substantial risks, including navigating bankruptcy proceedings, maintaining operational stability, and addressing financial obligations. Investors should closely monitor the reorganization process and assess the long-term viability of Invitae's business model. The company's negative profit margin of -601.6% and current market capitalization of $0.00B highlight the financial challenges it faces.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Filed for Chapter 11 reorganization on February 13, 2024, indicating significant financial distress.
- Offers a wide range of genetic tests across various clinical areas, including hereditary cancer, precision oncology, and rare diseases.
- Serves a diverse customer base, including patients, healthcare providers, and biopharma companies.
- Gross margin of 19.2% indicates challenges in achieving profitability.
- Profit margin of -601.6% reflects substantial losses and financial instability.
Competidores y Pares
Fortalezas
- Comprehensive genetic test menu.
- Established relationships with healthcare providers.
- Proprietary technology and data analytics.
- Strong brand recognition.
Debilidades
- Chapter 11 bankruptcy filing.
- Negative profit margins.
- High operating expenses.
- Significant debt burden.
Catalizadores
- Ongoing: Restructuring efforts to reduce debt and improve financial stability.
- Upcoming: Potential emergence from Chapter 11 bankruptcy with a viable reorganization plan.
- Ongoing: Strategic partnerships to expand market reach and service offerings.
Riesgos
- Ongoing: Chapter 11 bankruptcy proceedings and potential liquidation.
- Potential: Failure to secure necessary financing for restructuring.
- Potential: Loss of key customers or partnerships.
- Ongoing: Intense competition in the genetic testing market.
- Potential: Regulatory changes and reimbursement pressures.
Oportunidades de crecimiento
- Expansion into New Therapeutic Areas: Invitae can explore expanding its genetic testing services into emerging therapeutic areas such as neurodegenerative diseases and cardiovascular health. The market for genetic testing in these areas is growing, driven by advancements in research and increasing awareness of genetic risk factors. This expansion could provide Invitae with new revenue streams and market opportunities, although significant investment in research and development would be required.
- Strategic Partnerships with Biopharma Companies: Collaborating with biopharmaceutical companies to develop companion diagnostics and personalized treatment strategies represents a significant growth opportunity. The increasing focus on precision medicine drives demand for genetic testing to identify patients who are most likely to benefit from specific therapies. These partnerships can provide Invitae with access to new markets and revenue streams, while also enhancing its reputation and credibility within the healthcare industry.
- Geographic Expansion into Emerging Markets: Expanding its services into emerging markets, particularly in Asia and Latin America, could drive significant growth for Invitae. These regions have a growing demand for genetic testing due to increasing healthcare awareness and access to medical services. However, entering these markets requires careful consideration of regulatory requirements, cultural differences, and competition from local players.
- Development of Integrated Digital Health Solutions: Integrating genetic testing results with digital health platforms and tools can enhance patient engagement and improve healthcare outcomes. This includes developing mobile apps, online portals, and telehealth services that provide patients with personalized insights and support. The market for digital health solutions is rapidly growing, driven by increasing adoption of mobile technology and the need for more efficient and accessible healthcare services. This integration can differentiate Invitae from competitors and enhance customer loyalty.
- Focus on Rare Disease Diagnostics: Expanding its focus on rare disease diagnostics can provide Invitae with a niche market opportunity. Rare diseases often require specialized genetic testing to identify the underlying cause and guide treatment decisions. By offering comprehensive testing services for rare diseases, Invitae can address an unmet need in the healthcare market and establish itself as a leader in this area. This focus requires expertise in rare disease genetics and collaboration with specialized healthcare providers and patient advocacy groups.
Oportunidades
- Expansion into new therapeutic areas.
- Strategic partnerships with biopharma companies.
- Geographic expansion into emerging markets.
- Development of integrated digital health solutions.
Amenazas
- Intense competition in the genetic testing market.
- Regulatory changes and reimbursement pressures.
- Technological advancements that could render existing tests obsolete.
- Economic downturns that could reduce demand for genetic testing.
Ventajas competitivas
- Comprehensive test menu covering a wide range of clinical areas.
- Established relationships with healthcare providers and biopharma companies.
- Proprietary technology and data analytics capabilities.
- Brand recognition and reputation in the genetic testing market.
Acerca de NVTAQ
Invitae Corporation, founded in 2010 and formerly known as Locus Development, Inc., is a medical genetics company headquartered in San Francisco, California. The company focuses on providing comprehensive genetic information to enhance healthcare decisions across the United States, Canada, and internationally. Invitae offers a range of genetic tests covering various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics. These tests are designed to assist in diagnosis, treatment planning, and risk assessment for patients. In addition to genetic testing, Invitae provides digital health solutions and health data services, catering to patients, healthcare providers, biopharma companies, and other partners. The company aims to integrate genetic information into mainstream medical practice, making it more accessible and affordable. However, on February 13, 2024, Invitae and its affiliates filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of New Jersey, indicating substantial financial distress.
Qué hacen
- Provides genetic tests for hereditary cancer risk assessment.
- Offers genetic testing for precision oncology to guide cancer treatment decisions.
- Delivers genetic screening and diagnostic tests for women's health.
- Provides genetic testing for rare diseases to identify underlying causes.
- Offers pharmacogenomics testing to optimize medication selection and dosage.
- Develops digital health solutions to enhance patient engagement.
- Provides health data services to support research and development.
Modelo de Negocio
- Generates revenue through the sale of genetic testing services to patients and healthcare providers.
- Partners with biopharma companies to develop and commercialize companion diagnostics.
- Offers digital health solutions and health data services on a subscription or fee-for-service basis.
Contexto de la Industria
Invitae Corporation operates within the medical diagnostics and research industry, a sector characterized by rapid technological advancements and increasing demand for personalized medicine. The market is driven by the growing prevalence of genetic disorders and the need for early and accurate diagnosis. Competitive landscape includes established players like Roche and smaller, specialized genetic testing companies. Invitae's Chapter 11 filing reflects the challenges of scaling and achieving profitability in this competitive environment.
Clientes Clave
- Patients seeking genetic testing for risk assessment or diagnosis.
- Healthcare providers ordering genetic tests for their patients.
- Biopharma companies utilizing genetic testing for drug development and clinical trials.
Finanzas
Gráfico e información
Precio de la acción de Invitae Corporation (NVTAQ): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para NVTAQ.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para NVTAQ.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para NVTAQ.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de NVTAQ en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Competidores y Pares
Liderazgo: Kenneth D. Knight
CEO
Kenneth D. Knight serves as the Chief Executive Officer of Invitae Corporation. His professional background and educational details are not provided in the source data. As CEO, he is responsible for overseeing the company's strategic direction, operational performance, and financial results. His leadership is critical during the company's Chapter 11 reorganization process.
Historial: Kenneth D. Knight's track record at Invitae is difficult to assess given the company's recent Chapter 11 filing. Key decisions during his tenure will likely focus on restructuring the company's operations, reducing debt, and securing new financing. The success of these efforts will determine the company's long-term viability.
Información del mercado OTC de NVTAQ
The OTC Other tier represents the lowest tier of the OTC market, indicating that Invitae Corporation (NVTAQ) may not meet the minimum financial or regulatory requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure and may be undergoing financial distress or restructuring. Trading on the OTC Other tier carries higher risks compared to exchanges like NYSE or NASDAQ due to less stringent listing standards and potentially lower liquidity. Investors should exercise caution and conduct thorough due diligence before investing in companies on this tier.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure increases information asymmetry.
- Lower liquidity can lead to price volatility and difficulty in trading shares.
- Chapter 11 bankruptcy introduces significant uncertainty about the company's future.
- Potential for delisting from the OTC market.
- Higher risk of fraud or manipulation compared to listed exchanges.
- Verify the company's financial condition and review available financial statements.
- Assess the company's Chapter 11 reorganization plan and potential outcomes.
- Research the background and experience of the company's management team.
- Evaluate the company's competitive position and market outlook.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Established history as a provider of genetic testing services.
- Existing relationships with healthcare providers and biopharma companies.
- Proprietary technology and data analytics capabilities.
- Continued operation during the Chapter 11 reorganization process.
NVTAQ Preguntas Frecuentes sobre Acciones de Healthcare
¿Cuáles son los factores clave para evaluar NVTAQ?
Invitae Corporation (NVTAQ) actualmente tiene una puntuación IA de 41/100, indicando puntuación baja. Fortaleza clave: Comprehensive genetic test menu.. Riesgo principal a monitorear: Ongoing: Chapter 11 bankruptcy proceedings and potential liquidation.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de NVTAQ?
NVTAQ actualmente puntúa 41/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de NVTAQ?
Los precios de NVTAQ se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre NVTAQ?
La cobertura de analistas para NVTAQ incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en NVTAQ?
Las categorías de riesgo para NVTAQ incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Ongoing: Chapter 11 bankruptcy proceedings and potential liquidation.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de NVTAQ?
La relación P/E para NVTAQ compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está NVTAQ sobrevalorada o infravalorada?
Determinar si Invitae Corporation (NVTAQ) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de NVTAQ?
Invitae Corporation (NVTAQ) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available sources and may be incomplete due to the company's Chapter 11 status.
- Financial data may not be up-to-date due to the company's financial distress.